North America

Howard University president emeritus: ‘I don’t think you’ll hear of us trying to exit through secondary markets’

Secondaries has become a popular portfolio management tool for large US endowments like Yale and Harvard.

Bullish managers expect to utilise GP-leds more in the coming years – DC Advisory

The GP-led market is predicted to reach about $93bn in total volume this year, according to a report.

Houlihan Lokey’s co-head of GP-led advisory departs for Lazard

Sameer Shamsi will continue his focus on GP-led secondaries advisory at Lazard, Secondaries Investor understands.

Spotlight on LPACs in high-profile continuation vehicle spat

Do limited partner advisory committees have any relevance in a world where a sole LP wants to have its day in court?

CVs unlikely to ‘disappear’ because GPs ‘recognise their viability’ – TPG

CVs continue private equity’s history of innovation and evolution and will likely become part of the asset class’s long term set of options for exits, co-managing partners Jeff Rhodes told affiliate title Buyouts.

PJT MD Ayesha Hussain departs

Other recent moves at PJT include the exit of a principal to Bank of America, and the hire of a senior investment professional from NYCRS as a director.

NEA spin-out NewView targets $400m for latest VC secondaries fund

NewView Capital Fund IV arrives in the market as venture secondaries are heating up, driven by overallocated LPs pressing GPs to expand distributions as a way to replenish capital stocks.

Hobe Mountain: Missing data offers opportunity at small end of the market

The firm’s spin-out of Carlyle Group co-founder David Rubenstein’s single-family office Declaration Capital allows it to take on third-party capital and scale, co-founder Alexa Rachlin told Secondaries Investor.

A&M Capital targets $500m for debut secondaries fund

The fund will primarily focus on single-asset CV transactions, with additional flexibility to pursue multi-asset CVs and LP-led opportunities, Secondaries Investor has learned.

Healthcare specialist Amulet Capital runs CV-on-CV process for US Fertility

The single-asset process is part of what looks to be record-setting secondaries activity this year that appears headed for more than $200bn of total volume.